Aug. 30, 2012—Racial differences exist in quality surgical care, new research from VICC finds.
Aug. 16, 2012—A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy, and may offer a way to further refine personalized cancer treatments.
Aug. 9, 2012—Maryville, Tenn., tucked in the foothills of the Great Smoky Mountains, has a population of just 27,000, but it seemed like every one of its residents rallied around 20-year-old Brently Mancini when he was diagnosed with a rare soft tissue cancer.
Aug. 2, 2012—Carlos Arteaga, M.D., associate director for Clinical Research and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named to the Scientific Advisory Board of the Susan G. Komen for the Cure Breast Cancer Research Foundation.
Jul. 26, 2012—An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.
Jul. 20, 2012—High consumption of vitamin E either from diet or vitamin supplements may lower the risk of liver cancer, according to a study published July 17 in the Journal of the National Cancer Institute. The study was conducted by investigators from the Shanghai Cancer Institute, Vanderbilt-Ingram Cancer Center and the National Cancer Institute. Vitamin E is...
Jul. 12, 2012—Chin Chiang, Ph.D., professor of Cell and Developmental Biology and member of the Vanderbilt-Ingram Cancer Center faculty, has been awarded a $200,000 grant to study an aggressive form of childhood cancer.
Jul. 12, 2012—Olympic gold medal skating champion and cancer survivor Scott Hamilton was the keynote speaker at Vanderbilt-Ingram Cancer Center’s annual cancer survivors day event held at the Vanderbilt Student Life Center. Nearly 600 people attended “Going for the Gold: Living Well through Cancer,” which featured activities for cancer patients, survivors, friends and families. (photo by Debra...
Jul. 12, 2012—An experimental drug that activates T-cells and promotes an immune response to fight tumors has shown promising early results in patients with kidney cancer, melanoma and non-small cell lung cancer. Vanderbilt-Ingram Cancer Center investigators Leora Horn, M.D., Jeffrey Sosman, M.D., and researchers from several other cancer centers tested the new compound. The results of the...